Kadmon Holdings Inc. (NYSE: KDMN) reported positive results from an ongoing Phase 2 study of KD025 in patients with idiopathic pulmonary fibrosis who were previously treated with pirfenidone and/or nintedanib but the stock price plummeted $1.03 to close at $3.81.